135 related articles for article (PubMed ID: 16041400)
1. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures.
Wang G; Franklin R; Hong Y; Erusalimsky JD
Br J Pharmacol; 2005 Oct; 146(3):324-32. PubMed ID: 16041400
[TBL] [Abstract][Full Text] [Related]
2. Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage.
Hong Y; Wang G; Del Arroyo AG; Hernandez J; Skene C; Erusalimsky JD
Leukemia; 2006 Jun; 20(6):1117-22. PubMed ID: 16557242
[TBL] [Abstract][Full Text] [Related]
3. Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction.
Ahluwalia M; Donovan H; Singh N; Butcher L; Erusalimsky JD
J Thromb Haemost; 2010 Oct; 8(10):2252-61. PubMed ID: 20586925
[TBL] [Abstract][Full Text] [Related]
4. Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms.
Espasandin YR; Glembotsky AC; Grodzielski M; Lev PR; Goette NP; Molinas FC; Marta RF; Heller PG
J Thromb Haemost; 2015 Apr; 13(4):631-42. PubMed ID: 25604267
[TBL] [Abstract][Full Text] [Related]
5. A preliminary investigation into the action of anagrelide: thrombopoietin-c-Mpl receptor interactions.
McCarty JM; Melone PD; Simanis JP; Kanamori D; Dessypris EN; Warshamana-Greene GS
Exp Hematol; 2006 Jan; 34(1):87-96. PubMed ID: 16413395
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human primary megakaryocyte differentiation by anagrelide: a gene expression profiling analysis.
Sakurai K; Fujiwara T; Hasegawa S; Okitsu Y; Fukuhara N; Onishi Y; Yamada-Fujiwara M; Ichinohasama R; Harigae H
Int J Hematol; 2016 Aug; 104(2):190-9. PubMed ID: 27084257
[TBL] [Abstract][Full Text] [Related]
7. The effects of anagrelide on human megakaryocytopoiesis.
Solberg LA; Tefferi A; Oles KJ; Tarach JS; Petitt RM; Forstrom LA; Silverstein MN
Br J Haematol; 1997 Oct; 99(1):174-80. PubMed ID: 9359521
[TBL] [Abstract][Full Text] [Related]
8. Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603)?
Erusalimsky JD; Hong Y; Franklin R
Exp Hematol; 2002 Jul; 30(7):625-6; author reply 626-7. PubMed ID: 12135656
[No Abstract] [Full Text] [Related]
9. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans.
Mazur EM; Rosmarin AG; Sohl PA; Newton JL; Narendran A
Blood; 1992 Apr; 79(8):1931-7. PubMed ID: 1562721
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
[TBL] [Abstract][Full Text] [Related]
11. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia.
Tomer A
Blood; 2002 Mar; 99(5):1602-9. PubMed ID: 11861274
[TBL] [Abstract][Full Text] [Related]
12. Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation.
Lane WJ; Hattori K; Dias S; Peerschke EI; Moore MA; Blanset DL; Lang PC; Petrone M; Rafii S
Exp Hematol; 2001 Dec; 29(12):1417-24. PubMed ID: 11750100
[TBL] [Abstract][Full Text] [Related]
13. [Essential thrombocythemia: therapy with anagrelide].
Mazzucconi MG; Ferrari A; Balduini CL
Haematologica; 1991 Jun; 76 Suppl 3():378-81. PubMed ID: 1661268
[No Abstract] [Full Text] [Related]
14. CD226 is expressed on the megakaryocytic lineage from hematopoietic stem cells/progenitor cells and involved in its polyploidization.
Ma D; Sun Y; Lin D; Wang H; Dai B; Zhang X; Ouyang W; Jian J; Jia W; Xu X; Jin B
Eur J Haematol; 2005 Mar; 74(3):228-40. PubMed ID: 15693793
[TBL] [Abstract][Full Text] [Related]
15. Expansion of megakaryocyte precursors and stem cells from umbilical cord blood CD34+ cells in collagen and liquid culture media.
Shaw PH; Olszewski M; Kletzel M
J Hematother Stem Cell Res; 2001 Jun; 10(3):391-403. PubMed ID: 11454314
[TBL] [Abstract][Full Text] [Related]
16. Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34(+) hematopoietic progenitor cells.
Cheng L; Qasba P; Vanguri P; Thiede MA
J Cell Physiol; 2000 Jul; 184(1):58-69. PubMed ID: 10825234
[TBL] [Abstract][Full Text] [Related]
17. Effects of recombinant human thrombopoietin alone and in combination with erythropoietin and early-acting cytokines on human mobilized purified CD34+ progenitor cells cultured in serum-depleted medium.
Birkmann J; Oez S; Smetak M; Kaiser G; Kappauf H; Gallmeier WM
Stem Cells; 1997; 15(1):18-32. PubMed ID: 9007219
[TBL] [Abstract][Full Text] [Related]
18. [Anagrelide--new antiplatelet drug].
Robak T; Treliński J; Hołub A
Acta Haematol Pol; 1994; 25(4):309-15. PubMed ID: 7847031
[TBL] [Abstract][Full Text] [Related]
19. Flt3/Flk-2-ligand in synergy with thrombopoietin delays megakaryocyte development and increases the numbers of megakaryocyte progenitor cells in serum-free cultures initiated with CD34+ cells.
Sigurjónsson OE; Gudmundsson KO; Haraldsdóttir V; Rafnar T; Gudmundsson S
J Hematother Stem Cell Res; 2002 Apr; 11(2):389-400. PubMed ID: 11983110
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of thrombopoietic-stimulatory factor and spleen cell-conditioned medium on megakaryocytopoiesis in a short-term bone marrow liquid culture system.
Petursson SR; Chervenick PA
Exp Hematol; 1988 Sep; 16(8):660-6. PubMed ID: 3261250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
